Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00856284 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus
A Phase 3 study of Type 2 Diabetes Mellitus, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,639
- Enrollment target
- 20
- Study locations
NCT00856284 is a Phase 3 study of Type 2 Diabetes Mellitus that has completed, run by Takeda. The registered enrollment target is 2,639 participants, roughly in line with the 2,727-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target. The trial reports 20 study locations across 3 states.
The verdict
NCT00856284, a Phase 3 study of Type 2 Diabetes Mellitus, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,639 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety and effectiveness of adding alogliptin, once daily (QD), compared to glipizide with metformin in diabetic patients.
Conditions Studied
Interventions
- DRUG Metformin
- DRUG Glipizide
- DRUG Alogliptin
Study Locations (20)
California
- - Anaheim
- - Artesia
- - Chico
- - Los Alamitos
- - Mission Viejo
- - National City
- - Northridge
- - Pismo Beach
- - Riverside
- - Roseville
- - Sacramento
Arizona
- - Mesa
- - Peoria
- - Phoenix
- - Sierra Vista
- - Tempe
- - Tucson
Alabama
- - Montgomery
- - Muscle Shoals
- - Pell City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,639 participants |
| Start Date | 2009-03 |
| Est. Completion | 2012-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00856284
The ClinicalTrials.gov registry entry for NCT00856284 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,639 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 2,727-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 3 interventions - of which Metformin is the first listed.
NCT00856284 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT00856284 about?
NCT00856284 is a clinical study titled "Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus". The purpose of this study is to determine the safety and effectiveness of adding alogliptin, once daily (QD), compared to glipizide with metformin in diabetic patients.
What is the current status of trial NCT00856284?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,639 participants. The study started on 2009-03. Estimated completion is 2012-10.
What conditions does trial NCT00856284 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT00856284?
The interventions under investigation include: Metformin (DRUG), Glipizide (DRUG), Alogliptin (DRUG).
Who is sponsoring clinical trial NCT00856284?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00856284 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
RECRUITING · Phase 3
-
A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
COMPLETED · Phase 3
-
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
COMPLETED · Phase 3
-
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
COMPLETED · Phase 3
-
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.